News & Updates
Filter by Specialty:
ACE inhibitors, ARBs put brakes on emphysema progression, lung function decline in COPD
Angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear to be beneficial to chronic obstructive pulmonary disease (COPD) patients, with a recent study suggesting that the use of such drugs may slow down progression of emphysema and lung function decline.
ACE inhibitors, ARBs put brakes on emphysema progression, lung function decline in COPD
10 Oct 2021
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
09 Oct 2021
Ketone supplements may promote better brain health in obese adults
Ketone supplements containing β-hydroxybutyrate yield potential neurocognitive benefits in individuals with obesity, specifically bolstering cognitive function and increasing cerebral blood flow, as reported in a recent study.
Ketone supplements may promote better brain health in obese adults
08 Oct 2021
Antiviral monoclonal antibody therapies may prevent hospitalization in nonsevere COVID-19
The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.
Antiviral monoclonal antibody therapies may prevent hospitalization in nonsevere COVID-19
08 Oct 2021
Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA
The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.
